Rufinamide PurCert Secondary Reference Standard (CRM) [Includes all characterization data]
PurCert
Properties
| Water Solubility | Insoluble |
| Assay Purity | >=98% |
| M pt. | 236 - 237 °C |
| Density | 1.520 ± 0.1 g/cm3 |
| Form | Solid |
Safety Information
| Hazard Statement(s) | H336,H351,H361fd |
| Precautionary Statement | P202 - P261 - P271 - P280 - P304 + P340 + P312 - P308 + P313 |
| GHS Pictogram |
|
| Signal word | Warning |
| HS Code | 29339900 |
| Flash point | 2°C |
| Storage Temp. | Room Temperature |
| Storage Class | 11 - Combustible Solids |
| UN Number | NA |
Description
Application
It is administered orally as tablets or suspension (typically 200-400 mg twice daily for adults titrated based on response) for long-term management of seizures in patients with Lennox-Gastaut syndrome.
Purpose
Rufinamide treats refractory seizures associated with Lennox-Gastaut syndrome a severe childhood epilepsy by prolonging the inactive state of voltage-gated sodium channels to stabilize neuronal membranes and reduce hyperexcitability.
General Description
Rufinamide is a white to off-white crystalline powder it is chemically described as 1-(26-difluorobenzyl)-1H-123-triazole-4-carboxamide a triazole derivative with poor water solubility.
Documents
| SDS | |
| COA | |
| Specification | |
| Bulk quote order form | |
| Sample COA |
